Pioneering a Path to Better Cancer Therapies
All-in-one solution to get deeper cellular insights, reduce late-stage failures and bring better therapies to patients, faster.
Bridging the Gap in Cancer Drug Development:
The Nanolive Advantage
Cancer represents an immense global burden, causing significant mortality and morbidity, with millions of lives affected annually, underscoring the urgent need for more effective therapies. The emergence of new cancer therapies is hindered by costly clinical trials and high drug attrition rates, rooted in the failure to accurately predict the efficacy and safety of drug candidates in preclinical drug discovery. Accordingly, more than 90% of clinical phase drugs ultimately fail to make it to market.
Better preclinical, cell-based assays are required to narrow down optimal lead candidates, and thereby reduce the costs and resources associated with late-stage withdrawal. Nanolive is a all-in-one phenotypic screening solution to deliver reliable, real-time unbiased data during early-stage drug development, empowering researchers to make informed decisions about the best cell therapy, cell engager or immuno-modulator, ADC or small molecule drug, and gene therapy. Join Nanolive to advance the frontier of next-generation cancer therapies.
Dr. John Ferbas
Director, Cytometry and Imaging Sciences
“Nanolive has developed a ‘one-click assay’ with no staining or centrifugation required, just a high-quality cell culture plus or minus the treatments of interest. This will allow us to learn orders of magnitude more about cell biology with less effort, less cost and greatly reduced infrastructure requirements relative to our legacy approaches.”
Watch the full testimonial here
Prof. Douglas Hanahan
Professor Emeritus
“The Nanolive technology is like putting on 3D glasses in a cinema – visualizing in depth cellular phenomena that are otherwise opaque and obscure.”
Select effective cell therapy candidates in 1 shot
Leverage high-content, live-cell data to characterize the entire immune cell response with Nanolive’s T cell killing assay
Nanolive’s T cell killing assay characterizes immune cell finding, binding, and killing, all in a single automated cell culture cytotoxicity solution. Validate the selectivity, potency, and persistence of your cell therapy. Compare your candidates in 96-well plates.
The only 100% label-free solution for classification of cells in co-culture
Observe unperturbed effector and target cell interactions, without chemical labels or environmental bias for more accurate data. Nanolive’s T cell killing assay collects simultaneous measurements, reduce the effect of inter-experimental variation, the amount of sample required, and hands-on experimental time.
Automatically quantify effector dynamics
Gain insights to the activity and T cell proliferation over time. Visualize Activation-Induced Cell Death or understand effector persistence.
Measure effector/target interactions LIVE
Seven ways to quantify and validate how your effector therapy interacts with adherent targets. Determine subtle differences in mechanism of action, such as changes in binding duration and the percentage of effectors bound at every time point.
Assess effector fitness and select the best killers
Automatically quantify serial killing of targets over time and use the high-resolution images for visual confirmation. Eliminate exhausted effector cell variants from your pipeline, thanks to measurement of deceleration or cessation of T cell killing.
Find the cell engager or immuno-modulator linked to the optimal effector response
Determine if a cell engager or immune-modulator influences effector cell activation
Using fluorescence reporter genes of T cell activation, automatically quantify how many T cells are activated over time following the addition of the therapy in question. Metrics like T cell count can give insights to proliferative effects.
Investigate if the engager improves recruitment of effector cells to tumor cells
Seven ways to determine if there are changes in tumor cell finding and binding.
Discover if the treatment alters target killing efficiency
Test different candidates in parallel to identify which is the most efficient. Use our dynamic cell death data to understand the kinetics of the effector response.
Measure cytotoxicity and bystander effects of small molecules and antibody drug conjugates
The only 100% label-free solution to classify apoptosis vs necrosis
Nanolive’s cell cytotoxicity assay determines the effectiveness of drug candidates in killing cancer cells, with automated segmentation and classification of cells as living, apoptotic or necrotic, in every field of view/every timepoint, without the need for any labels. Increase confidence in leads knowing that the cytotoxicity you see is due to your drug and is free of bias due to chemical labels.
Quantify off-target effects of ADCs and small molecule drugs
Test the selectivity of your drug candidates by measuring their cytotoxicity in co-culture. Determine the selectivity and bystander killing profile of ADC candidates by separately measuring death of antigen positive and negative cells within a co-culture. Eliminate candidates with non-selective effects from your pipeline.
Quantify dose-response and cell death kinetics
Test different drug concentrations in parallel. With quantification of cell death at every time point, generate dynamic EC50 curves.
Empowering gene therapy research: from uptake to cellular response
Quantify gene therapy uptake in cells
With Nanolive’s automated analysis, measure the incorporation/uptake of fluorescent vectors, such as lipid nanoparticles carrying your gene therapy, into target cells. Our automated system calculates fluorescence intensity per cell at each time point, providing a reliable indicator of vector uptake.
Verify gene therapy expression in cells
Employ fluorescent reporter genes and Nanolive’s automated fluorescence intensity analysis to quantitatively verify gene therapy expression while simultaneously capturing dynamic live cell images. This comprehensive approach allows for evaluation of the efficacy of your gene therapy.
Assess cellular phenotypic responses to treatment with a gene therapy
Thirteen essential metrics are automatically calculated for the entire acquisition, ranging from area and perimeter to granularity and dry mass, permitting unbiased monitoring of phenotypic changes induced by your treatment.
Determine cytotoxicity of a gene therapy, label-free
Gain insights into the cytotoxicity of your gene therapy with automated cell health classification, distinguishing living, apoptotic, and necrotic cells at every time point. Determine the time to death induced by the gene therapy and differentiate between apoptotic and necrotic cell death types, aiding in the selection of optimal gene therapy candidates.
Assess heterogeneous effects of a gene therapy in a population or co-culture
Using fluorescence, leverage Nanolive’s software to automatically identify distinct cell populations within co-cultures, such as healthy and cancerous cells. Upon introduction of your gene therapy, easily determine whether phenotypic or cytotoxic effects are specific to a particular sub population of cells.
Evaluate gene therapy efficacy in modulating effector cell function
Investigating the potential of a gene therapy to enhance cancer cell targeting by CAR-T, T cells or NK cells? Validate its efficacy with Nanolive’s automated analysis of effector cell finding, binding and killing of cancer cells. Learn more about Nanolive’s comprehensive solutions for cell therapy development here.
Boost Discovery of Cancer Therapies with High-Content, Label-Free Live Cell Imaging and Analysis
Unlock the power of unlimited high-content live cell analysis with Nanolive’s label-free data. Our AI-powered portfolio of digital assays enables analysis and re-analysis of label-free, live cell image data generated by our unique holotomography approach. Our simple, autonomous workflow ensures that your precious time in the lab is used efficiently, and you can trust that your samples are in good hands, whether you are imaging for an hour, or days.
Streamlined, automated workflows: save time and money
Long-term monitoring of cells label-free
High content, multiplexed, reliable live cell data
Fully integrated, cutting-edge digital analysis solutions